ATTD: Advanced Technologies and Treatments for Diabetes

ATTD is the leading forum for the latest in diabetes research, technology, and clinical innovation. This podcast offers two types of content for healthcare professionals:* ATTD Conference Catch-up: AI-generated episodes with key insights from expert presentations & research discussions.* Curated Series: Human-led conversations such as ATTD Tech Connect (sponsored by Medtronic), and previously Long-Acting Insulin Uncovered (supported by Eli Lilly and Company) and CGM in Focus (supported by Dexcom).Whether you're a specialist, researcher, or industry leader, hit subscribe.

ATTD: Advanced Technologies and Treatments for Diabetes is a science podcast hosted by ATTD on UNLOK, with 80 episodes on record and a Required Pod Score of 80.

ATTD on UNLOK hosts ATTD: Advanced Technologies and Treatments for Diabetes, a science show with 80 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #2

  The Science Behind Weekly Insulin

  Sep 22, 202622 minS3

  In this episode, we explore the science behind weekly insulin, including the pharmacology of weekly insulin, its mechanism of action, how it differs from daily insulin formulations, and why it provides consistent control over a longer period. Guest: Dr. Manasi Shah, Assistant Professor of Medicine at Eastern Virginia Medical School and Director of the Inpatient Diabetes Program at Sentara Norfolk General Hospital Key discussion points: What are the key pharmacokinetic properties that enable once-weekly insulin administration? How does the pharmacodynamic profile differ from that of daily basal insulin formulations? What mechanisms allow weekly insulin to provide sustained glucose control over several days? How does this prolonged action translate into clinical glycemic stability? What are the key pharmacological considerations clinicians should be aware of when interpreting data on weekly insulin? What remaining scientific questions need to be addressed before broader clinical adoption? You can find more resources on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field. This series is supported by Eli Lilly & Company

  ListenShow Notes
• 

  Episode #1

  The Weekly Insulin Breakthrough

  Sep 8, 202619 minS6

  In this inaugural episode of ATTD Diabetes Talks: The Power of Weekly Insulin , we delve into the evolution and future of basal insulin therapy. Host Diana Isaacs sits down with Dr. Rodolfo Galindo to explore the pharmacological innovations behind weekly insulin formulations and discuss how this breakthrough is reshaping modern diabetes management. Guest: Dr. Rodolfo Galindo (Associate Professor of Medicine and Director of the Comprehensive Diabetes Center at the University of Miami Health System) Key Topics Covered: The Evolution of Basal Insulin: A look back at the progression from early long-acting formulations to current weekly treatment options. Pharmacological Innovation: Understanding the science that makes weekly insulin formulations possible. Clinical Advantages: Exploring the theoretical benefits of weekly versus daily basal insulin. Patient Impact: Examining how shifting to a weekly regimen affects treatment burden and overall patient experience. Future Outlook: How weekly insulin is poised to fit into the broader landscape of diabetes care. Resources: For more in-depth knowledge and exclusive content, visit the ATTD Education Portal . Subscribe to the podcast to stay updated on the latest in diabetes management.

  ListenShow Notes
• 

  ATTD: Advanced Technologies and Treatments for Diabetes

  Unmet needs in paediatric diabetes – the potential role of inhaled insulin

  Aug 25, 202625 min

  Join host Dr. David Ahn and guest Dr. Michael Haller (Professor and Chief of Pediatric Endocrinology at the University of Florida and Chair of TrialNet) as they take a comprehensive review of the evidence base and remaining gaps for inhaled insulin use in pediatric and adolescent populations In this final episode, we dive into: Key Challenges in Pediatrics: Unmet needs in pediatric insulin therapy, including injection fatigue and tech-retention issues for active youth. The INHALE-1 Study: A deep dive into the randomized controlled trial data of 230 youth, highlighting efficacy, per-protocol non-inferiority, less weight gain, and superior treatment satisfaction among kids and parents. Safety Profile: Analyzing forced expiratory volume (FEV1) data showing an excellent safety signal with no differences in pulmonary function or severe hypoglycemic events. Practical Toolkit Use Cases: How the unique pharmacokinetic profile of inhaled insulin provides unmatched benefits for covering adrenaline-rush highs and avoiding hypoglycemia tail effects during sports and exercise. Dosing Guidelines: Overcoming the practical "paradigm shift" of converting injected units to inhaled units and managing dosing effectively. Future Horizons: Anticipating the "INHALE FIRST" study investigating early onboarding for newly diagnosed patients and introducing a new two-unit inhaled insulin cartridge. About ATTD Diabetes Talks: A podcast series dedicated to providing healthcare professionals with the latest knowledge and best practices in diabetes management, supported by MannKind Corporation. Find more resources on the ATTD Education Portal: https://unlok-education.com/attd/ Subscribe to the podcast for more updates on advancing diabetes care. #DiabetesManagement #PediatricEndocrinology #InhaledInsulin #ATTD #DiabetesCare #MedicalPodcast #Type1Diabetes Chapters: 00:00 Intro and Unique Challenges in Pediatric Diabetes Management 02:38 The INHALE-1 Study: Efficacy, Satisfaction, and Weight Findings 06:27 Safety Signals, Pulmonary Function, and Adherence Challenges 10:18 Practical Toolkit Use Cases: Managing Sports and Exercise 12:48 Dosing Conversions and Practical Patient Selection Guidelines 15:02 Off-Label Integration with Automated Insulin Delivery (AID) Systems 20:14 Caregiver & School Nurse Roles and Managing Safety Concerns 22:00 Research Gaps, The INHALE FIRST Trial, and Wrap Up

  ListenShow Notes
• 

  ATTD: Advanced Technologies and Treatments for Diabetes

  Overcoming therapeutic inertia with inhaled insulin

  Aug 11, 202617 min

  In this episode, we examine the concept of "therapeutic inertia" in diabetes care. Dr. David Ahn is joined by Dr. Grazia Aleppo, Professor of Medicine at the Feinberg School of Medicine, Northwestern University, to explore how inhaled insulin can help address the clinical and behavioral barriers often associated with insulin initiation. Key discussion points: Defining therapeutic inertia in the context of insulin initiation. Common clinician and patient-related barriers that contribute to treatment delays. Practical strategies for introducing inhaled insulin to hesitant patients. System-level considerations, including workflow and reimbursement challenges. Find more resources and exclusive content on the ATTD Education Portal: https://unlok-education.com/attd/ Make sure to subscribe to the ATTD Diabetes Talks podcast for more insights and updates. Let’s advance diabetes care together. #DiabetesCare #Endocrinology #InhaledInsulin #ATTD #MedicalPodcast Chapters: 00:00 Why Inhaled Insulin Matters 00:34 Show Intro and Guest 01:22 Defining Therapeutic Inertia 02:19 Clinician Barriers to Insulin 03:49 Patient Fears and Hesitation 05:28 How Inhaled Insulin Helps 07:00 Best Fit Patient Scenarios 08:22 Talking to Hesitant Patients 10:39 Workflow and Coverage Hurdles 13:35 PFT Testing and Side Effects 14:47 Future Role and Wrap Up

  ListenShow Notes
• 

  ATTD: Advanced Technologies and Treatments for Diabetes

  Addressing Clinicians’ FAQs on Insulin Therapy

  Jul 28, 202617 min

  In today’s episode, Dr Bob Gabbay is joined by Dr Elena Toschi to address the most common questions clinicians have when it comes to insulin therapy. They discuss: The most common mistakes or misconceptions in basal insulin initiation and management Intensification strategies such as titration, adding prandial insulin, or using fixed-ratio combinations Leveraging technologies to improve insulin adherence and outcomes Managing hypoglycemia concerns and achieving glycemic targets Addressing psychological and behavioral barriers to insulin use in everyday clinical practice Dr Elena Toschi is Assistant Professor of Medicine at Harvard Medical School. She’s also Director of the Young Adult Program and a member of the Diabetes Technology Program at the Joslin Diabetes Center. Explore more on the ATTD Education Portal . Register now to access exclusive content and stay ahead in the field! Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

  ListenShow Notes

Recent guests on ATTD: Advanced Technologies and Treatments for Diabetes. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.